Phase 3
Recruiting
Has No Placebo
This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors.
Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.
Phase 3
Recruiting
Has No Placebo
Novo Nordisk Investigational Site (+8 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S